KEGG   NETWORK: N10002Help
Entry
N10002                      Network                                

Name
Second/third-generation tyrosine kinase inhibitor to BCR-ABL fusion
Definition
(Dasatinib,Nilotinib,Bostinib,Ponatinib) -| BCR-ABL1*
  Expanded
(D06414,D06413,D09728,D09951) -| 25v2
Class
nt06210 ERK signaling
nt06276 Chronic myeloid leukemia
nt06214 PI3K signaling
nt06219 JAK-STAT signaling
Type
Drug target
Gene
25  ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase
Variant
25v2  First generation TKI-resistant ABL1 mutation
Perturbant
D06414  Dasatinib (second generation)
D06413  Nilotinib (second generation)
D09728  Bostinib (second generation)
D09951  Ponatinib (third generation)
Reference
  Authors
Jabbour E, Kantarjian H, Cortes J
  Title
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
  Journal
Clin Lymphoma Myeloma Leuk 15:323-34 (2015)
DOI:10.1016/j.clml.2015.03.006
Reference
  Authors
An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS
  Title
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
  Journal
Leuk Res 34:1255-68 (2010)
DOI:10.1016/j.leukres.2010.04.016

DBGET integrated database retrieval system